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Background. Our aimwasto study the impact ofclinicalacute rejection (CR) and subclinicalrejection (SR) onoutcomes in kidney
transplant recipients treated with rapid steroid withdrawal (RSW). Methods. All patients who received a living or deceased donor
kidney transplant and were treated with RSW were included. The primary outcome was death-censored graft survival. Biopsies
withBanﬀ borderline changes were included with the rejection groups. Results. 457 kidney transplant recipients treated with RSW
were included; 46 (10%) experienced SR, and 36 (7.8%) had CR. Mean HLA mismatch was signiﬁcantly higher in the CR group.
The Banﬀ grade of rejection was higher in the CR group. There was a larger proportion of patients in both rejection groups with
the combination of IFTA and persistent inﬂammation on the follow-up protocol biopsy done at 1 year. The estimated 5-year
death-censored graft survival was 81% in SR, 78% in CR, and 97% in the control group (P<. 0001). Signiﬁcant diﬀerences were
observed in allograft survival between the CR and control group (HR 9.06, 95% CI 3.39–24.2) and between the SR and control
group (HR 4.22, 95% CI 1.30–13.7). Conclusion. Both SR and CR are associated with an inferior graft survival in recipients on
RSW.
1.Introduction
The process of allorecognition and acute rejection is an
important mechanism of kidney allograft damage resulting
in interstitial ﬁbrosis and tubular atrophy (IFTA). T-cell-
mediated rejection is characterized by inﬁltration of the
interstitium and tubules by T cells and macrophages [1–
3]. The eﬀector response results in inﬂammation, epithelial
dediﬀerentiation, and epithelial-to-mesenchymal transition
with subsequent graft ﬁbrosis [4]. Acute rejection can cause
graft dysfunction and be clinically apparent, or it can be
clinically silent and found only by surveillance biopsy [4,
5]. Most acute rejection is classiﬁed as cellular rejection
resultingfrom allorecognitionandT-cell-mediated response.
But a small fraction of patients who are nonsensitized before
transplant will develop de novo donor-speciﬁc HLA anti-
bodies resulting in endothelial injury and a phenotype that
is classiﬁed as antibody-mediated rejection [6]. With mod-
ern immunosuppression protocols, which usually include
induction therapy, a calcineurin inhibitor, mycophenolate
mofetil, and steroids, the incidence of acute rejection is
between 10 and 20% [7–9]. Clinical studies have shown that
acute rejection, including subclinical acute rejection (SR), is
associated with inferior graft survival [5, 10, 11], but all of
these studies have been in patients on immunosuppression
containing chronic corticosteroid.
The utilization of rapid steroid withdrawal (RSW) pro-
tocolsin kidney transplant recipientshas gradually increased
over the last 10 years. In a recent analysis, more than 30% of
kidney recipients in the USA are treated with RSW protocols
[12]. Several studies have demonstrated that short- and
intermediate-term outcomes are similar to steroid-treated
patients[12].Inaddition,theriskofacuterejection issimilar
or slightly higher with RSW [12–14]. Recently, Woodle et al.
reported the results of a 5-year multicenter, randomized trial
of early steroid withdrawal [13]. They found that the risk
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Figure 1: Distribution of Banﬀ classiﬁcation of acute rejection.
Banﬀ borderline changes were included with the rejection groups.
The SR group had milder grades of acute cellular rejection
compared to the CR group (P<. 02 by chi-square). AMR occurred
in 14% of the CR group and 4% of the SR group (not signiﬁcant).
SR: subclinical rejection, CR: clinical rejection, AMR: antibody-
mediated acute rejection, Bord: borderline change by Banﬀ criteria.
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were not diﬀerent between the groups. However, none of
these studies have evaluated the impact of acute rejection,
particularly SR, on graft survival.
The aim of this current study is to look at the impact of
acute rejection, including SR, on graft outcomes, including
death-censored graft survival (DCGS), in patients on RSW.
2.PatientsandMethods
This study was approved by the Mayo Foundation Institu-
tional Review Board (IRB). This is a retrospective study of
all adult kidney transplant recipients treated with an RSW
protocol who were transplanted at our center between July
2003 and June 2008. Followup was to July of 2009. The
followingpatientswereexcluded:combinedorgantransplant
recipients, patients with pretransplant donor-speciﬁc anti-
body (DSA)or positiveﬂow cross-match, and recipients who
lost the graft within 30 days of transplantation. The primary
outcome was DCGS.
Posttransplant protocol biopsies were done at months 1,
4 and annually. Biopsies were performed in the outpatient
radiology department with real-time ultrasound guidance
using an 18g BioPince biopsy gun to obtain at least one
core. Protocol biopsies were interpreted using the Banﬀ ’05
criteria [15]. Beginning in 2004, C4d staining was routinely
done on the one-month biopsies, and beginning in 2006,
C4d was done on all biopsies. A positive C4d required
diﬀuse (greater than 50%) peritubular staining by either
immunoﬂuorescence or immunohistochemical techniques
[2]. All patients were routinely tested for BK viremia at
months 1, 4 and annually. A diagnosis of BK nephropathy
required BK viremia and a biopsy demonstrating BK by in
situ hybridization.
Log-rank test P<. 0001
SR versus no AR, P = .0075
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Figure 2: Kaplan-Meier survival curves for death-censored graft
survival. The 5-year estimate of the death-censored graft survival
is 78% in the CR and 81% in the SR groups and 97% in the control
group without acute rejection (log-rank P<. 0001). The number
of patients at risk at each time point is shown in the bottom of
the ﬁgure. Signiﬁcant diﬀerences in death-censored graft survival
were observed between the CR and control group (HR 9.06, 95%
CI 3.39–24.2) and between the SR and control group (HR 4.22,
95% CI 1.30–13.7); however there was no signiﬁcant diﬀerence
between the CR and SR groups (HR 2.14, 95% CI 0.63–7.28). NO
AR: control group without rejection, SR: subclinical rejection, CR:
clinical rejection.
All rejections were biopsy proven. Acute rejection
included both cellular rejection and antibody-mediated
rejection. Biopsies showing Banﬀ borderline changes were
included in the rejection groups. Clinical rejection (CR)
included all rejections found on biopsies done for cause
and associated with a creatinine increase of more than
23µmol/L and subclinical rejection (SR) included with a
serum creatinine that was within 23µmol/L of the previous
baseline. If the protocol biopsy showed rejection but the
creatinine wasmorethan 23µmol/Lhigherthantheprevious
established baseline, the biopsy was classiﬁed as CR. If a
patient had both CR and SR on two separate biopsies, they
were classiﬁed into the CR group.
The cause of graft failure was determined by analyzing
both clinical and pathology data. For this analysis, 3 of
the investigators independently classiﬁed the cause of graft
failure without knowledge of the rejection status. Diﬀerences
in classiﬁcation between the investigators occurred in 26%Journal of Transplantation 3
of the cases, and for these cases the cause was determined by
consensus.
2.1. Immunosuppression Protocol. Patients were eligible for
rapid steroid withdrawal if they met the following eligibility
criteria: negative pretransplant ﬂow cross-match, no pre-
transplant donor-speciﬁc antibodies, no previous history of
transplant lost due to acute rejection, PRA ≤ 20%, and not
on corticosteroids within 3 months of transplant.
All patients received induction with either rabbit anti-
thymocyte globulin (r-ATG) (6mg/kg, usually administered
in 4 divided doses) or basiliximab (total 40mg, given i.v.
in 2 divided doses). A small number received alemtuzumab
(30mg given SQ in a single dose) as part of a separate IRB-
approved protocol. Patients who were older than 70 years
of age or with a history of prior high risk malignancy or
infections received basiliximab while the remainder received
r-ATG. Tacrolimus was started when the serum creatinine
dropped by at least 30%, or by post-op day 4. The goal
for trough tacrolimus levels was 10–12ng/mL for the ﬁrst
30 days, 8–10ng/mL between days 30–90, and 5–8ng/mL
after 90 days. Mycophenolate mofetil (MMF) was started at
2000mg per day, in divided doses, and adjusted according
to the individual patient’s tolerance. The protocol for
corticosteroid use was methylprednisolone (MP) 500mg i.v.
onpost-opday(POD)0,MP250mgivPOD1,MP125mgiv
on POD 2, prednisone (P) 60mg po on POD 3, and P 30mg
po on POD 4.
2.2. Statistical Analysis. Comparison of the characteristics
between the groups (CR, SR, no rejection group) was done
using ANOVA and Student’s t-test for continuous variables
or chi-square for categorical data. A P value of less than .05
was required forstatistically signiﬁcance. All P valuesare two
sided. We measured the association of the rejection groups
to death-censored graft survival using survival analysis. We
compared unadjusted graft survival among the groups with
Kaplan-Meier analysis and the log rank test. We used Cox
proportional hazards analysis to measure the univariate
association of the rejection groups with death-censored graft
survival. Since the aim of the study was to determine the
impact ofacuterejection ongraft outcome,grafts lostduring




Between July 2003 and June 2008, 612 patients received a
kidney transplant alone at our center. Of these, 464 patients
(76%) were treated with the rapid steroid withdrawal
protocol.Sevenpatients(1.5%)lostthegraft duetotechnical
causes within 30 days of transplant and were excluded from
further analysis. For the remaining 457 patients, 46 (10%)
wereclassiﬁed asSRincludingBanﬀborderline changesin18
and acute rejection in 25. The CR group included 36 (7.8%)
patients including Banﬀ borderline changes in 4 or acute
rejectionin26.The remaining 375patientswithout rejection
served as the control group. The mean HLA mismatch was
signiﬁcantly higher in the CR group compared to the no
rejection group (3.94 versus 3.33,P<. 05),butnot forthe SR
group(3.74).Otherwise, therewerenosigniﬁcantdiﬀerences
in the baseline patient characteristics or the characteristics
of the transplant between the 3 groups, including recipient
demographics, donor characteristics, induction agent used
or the fraction with delayed graft function (Table 1). All
patients received induction. Numerically, more patients
received basiliximab induction in the CR and SR groups but
this was not statistically signiﬁcant. Only 3 patients received
inductionwithalemtuzumabandthebalancereceivedr-ATG
induction.
The protocol biopsy rates at each time point for the
control group, SR group, and CR group at 1 month were
86%, 89%, and 89% (ns), at 4 months 77%, 93%, and 67%
(P = .009), and at 1 year 57%, 76%, and 53% (P = .04).
There were no signiﬁcant diﬀerences in the management
of the maintenance immunosuppression (tacrolimus trough
levels, MMF dosing, steroid conversion) during the ﬁrst
posttransplant year between the three groups except that
more patients in the CR group had been converted to cor-
ticosteroids (55%) by one year posttransplant as compared
to 10% in the SR and 9% in the control group (Table 2).
3.1. Characteristics of the Acute Rejections and Follow-Up
Biopsy Findings. As would be expected, the serum creatinine
at the time of the biopsy was higher in the CR group
compared to the SR group (mean 343 ± 257 versus 133 ±
38µmol/L, resp., P<. 001). In addition, the rejections
in the SR group were milder and occurred later after
transplantation compared to the CR group (Table 3 and
Figure 1). For example, the percent classiﬁed with Banﬀ
borderline changes was 39% in the SR group and 11% in the
CR group. The diﬀerence in the overall Banﬀ classiﬁcation
of rejection between the groups was signiﬁcant (P<. 02 by
chi-square). Antibody-mediated rejection accounted for 4%
of the rejections in the SR group and 14% in the CR group
(diﬀerence not signiﬁcant). The C4d was positive (focal or
diﬀuse) in the peritubular capillaries in 29% of the SR group
and 19% of the CR group (diﬀerence not signiﬁcant). At the
time ofrejection,thefraction ofbiopsieswithan IFTA(Banﬀ
ci plus ct) greater than 2 was numerically higher in the SR
group (43% versus 24% in the CR group) but this diﬀerence
was not statistically signiﬁcant. The median number of days
from transplant to acute rejection was 130 in the SR group
and 19 in the CR group (P<. 05).
Next, we analyzed the ﬁndings on the 1-year protocol
biopsies which were done after the index biopsy for SR or
CR (Table 4). There were 35 1-year biopsies done in the SR
group (76% of the group) and 19 biopsies done in the CR
group (53% of the group). The ﬁndings were compared to
214 1-year biopsies in the control group (57% of control
group). The median number days from the index biopsy to
thefollowup1-yearbiopsywas223daysfortheSRgroupand
336daysforthe CRgroup(P<. 05).The means for the Banﬀ
i and t scores on the followup biopsies were signiﬁcantly
higher in the two rejection groups. In addition, the fraction4 Journal of Transplantation






(n = 36) P value
% of total 82% 10% 7.8%
Mean Age (years) 53.0 ±13.65 1 .3 ±14.15 2 .7 ±13.6. 7 4
Gender female 40% 33% 36% .68
Mean weight (Kg) 82.2 ±18.58 4 .1 ±23.68 9 .6 ±19.7. 0 8
%w i t hP R A> 0 8% 3% 18% .07
Preemptive Tx 27% 26% 19% .58
African American Race 6% 7% 11% .52
Pre Tx Diabetes 35% 43% 33% .51
Mean HLA mismatch 3.33 ± 1.79
∗ 3.74 ±1.74 3.94 ±1.51
∗
Basailiximabinduction 15% 24% 28% .08
Deceased donor 38% 46% 36% .56
Donor female 55% 50% 67% .68
Donor age (years) 41.3 ±13.94 1 .5 ±15.44 0 .4 ±14.4. 9 3
ECD donor 7% 7% 6% .93
DGF 13% 22% 22% .12
SR: subclinical rejection, CR: clinical rejection, Tx: transplantation, ECD: extended criteria donor, DGF: delayed graft function.
All continuous variables displayed as the mean ± standard deviation.
∗P<. 05 for CR versus no rejection.








Trough tacrolimus level (mean ± SD in ng/dL)
1m o n t h 10.7 ±2.91 0 .1 ±2.81 0 .9 ±4.1 .45
4m o n t h s 7.6 ±2.97 .4 ± 3.77 .7 ±2.6 .89
12 months 7.8 ±3.97 .6 ± 3.07 .0 ±3.2 .59
Mycophenolate mofetil dose (mean ± SD in mg/day)
1m o n t h 1673 ±412 1652 ±420 1607 ±540 .66
4m o n t h s 1392 ±478 1378 ±480 1383 ±486 .98
12 months 1261 ±476 1181 ±480 1223 ±468 .61
% of patients on corticosteroids
12 months 9%∗∗ 10%∗ 55%∗,∗∗ <.0001
SR: subclinicalrejection, CR: clinical rejection, SD; standard deviation.
∗P = .0002 for CR compared to SR group.
∗∗P<. 0001 for CR compared to No rejection group.
of biopsies with the combination of IFTA more than 2 and i
or t > 0 was 34% in the SR group and 24% in the CR group
and 8% in the control group (P<. 001 for SR compared to
the control group and P = .02 for CR compared to control
group).
T h e r ew e r es o m ed i ﬀerencesin the treatment of rejection
between the groups (Table 5). Overall, 72% received pulse
corticosteroids (74% in the CR group and 71% in the
SR group), 1.2% received r-ATG, 2.4% received IVIg, 10%
received therapeutic plasmapheresis, and 17% received an
upward adjustment in maintenance immunosuppression
(8% for CR group and 24% of the SR group). The diﬀerence
inthe overall categoriesoftreatment betweenthe groupswas
borderline signiﬁcant (P = .06 by chi-square). The average
number of doses of pulse corticosteroids (mean 2.5 versus
1.7, P = .003) and the total dose in mg (1240 ± 439 versus
863±446,P = .003)were both higherinCRgroup(Table 5).
There was a trend towards a larger fraction of CR group
(66%) remaining on corticosteroids after the treatment for
rejection compared to the SR group (43%) (P = .08).
Ten of the 18 patients (56%) with Banﬀ borderline
changes in the SR group were treated with pulse corticos-
teroids, and 3 of the 4 with Banﬀ borderline changes in
CR were treated with pulse corticosteroids (not signiﬁcant).
Seven of the 18 patients with Banﬀ borderline changes in
the SR group remained on corticosteroids, and 2 of the 4
patients with borderline changes in the CR group remained
on corticosteroids after the initial treatment.Journal of Transplantation 5
Table 3: Characteristics of Acute rejections.




130 (111–361) 19 (10.5–146) <.05
Serum creatinine
at biopsy in µmol/L
(mean ± SD)
133 ±38 343 ±257 <.001
Tacrolimus level in
ng/mL at time of
biopsy (mean ±
SD)
6.7 ±2.48 .8 ±3.4 .003
Mycophenolate
mofetil dose in
mg/day at time of
biopsy (mean ±
SD)
1228 ±524 1493 ±570 .03
Banﬀ grade of rejection .02∗
Borderline 18 (39%) 4 (11%)
Ia 16 (35%) 11 (31%)
Ib 5 (11%) 11 (31%)
IIa 4 (9%) 4 (11%)
IIb
III 1 (2%)
AMR 2 (4%) 5 (14%)
Peritubular C4d staining
C4d positive 10/34 (29%) 6/31 (19%) .51
Chronic changes
IFTA > 2 at Bx 43% 24% .11
SR: subclinical rejection, CR: clinical rejection, AMR: antibody mediated
rejection,IFTA:interstitialﬁbrosisandtubularatrophy (sumofBanﬀciplus
ct score).
∗ For the diﬀerence in the overall Banﬀ classiﬁcation of rejection by chi-
square test.
3.2. Death Censored Graft Survival (Figure 2). The occur-
rence of death with a functioning graft was not diﬀerent
between the three groups but death-censored graft loss was
higher in the two rejection groups (Table 5). Death-censored
graft loss occurred in 8.7% of the SR group, 19.4% of the CR
group compared to 2.4% of the control group (P<. 05).
Death-censored graft survival was lower for both the CR
and SR groups compared to the control group (log-rank
P<. 0001). The Kaplan-Meier estimate of graft survival at
5 years posttransplant was 78% and 81% for the CR and SR
groups, respectively, compared to 97% for the control group.
Signiﬁcant diﬀerences in death-censored graft survival were
observed between the CR and control group (HR 9.06, 95%
CI 3.39–24.2) and between the SR and control group (HR
4.22, 95% CI 1.30–13.7); however there was no signiﬁcant
diﬀerence between the CR and SR groups (HR 2.14, 95% CI
0.63–7.28).
When we combined the two rejection groups and
analyzed the death-censored graft survival for all patients
with Banﬀ subclinical changes compared to all patients with
acute rejection the HR for graft loss was 1.66 (95% CI 0.42–
6.3, P = .46). The 5-year estimated death-censored graft












to biopsy (median) 223 336∗
Banﬀ scores (mean value)
Interstitial
inﬂammation(i) 0.11 0.83∗# 0.35∗#
Tubulitis (t) 0.16 0.66∗ 0.59∗
Glomerulitis (g) 0.08 0.26 0.18
Interstitial ﬁbrosis
(ci) 0.97 1.43# 1.06
Tubular atrophy (ct) 1.18 1.51# 1.24
Intimal thickening
(cv) 0.59 0.43 0.56
Transplant
glomerulopathy (cg) 0.01 0.11# 0.06
IFTA > 2a n di / t> 0 8% 34% 24%∗∗
SAR: subclinical acute rejection, CAR: clinical acute rejection, AR: acute
rejection,IFTA:interstitialﬁbrosisand tubularatrophy (sumofBanﬀ ciplus
ct score).
∗P<. 05 comparing CAR to SAR.
#P<. 05 compared to No rejection.
P<. 0001 comparing SR to No rejection.
∗∗P = .02 comparing CR to No rejection.
Table 5: Treatment of acute rejection.
SR (n = 46) CR (n = 36)
∗
Pulse corticosteroids 32 (71%) 26 (72%)
Average number of doses 1.7 2.5∗∗
Total dose of pulse corticosteroid
(mg/day, mean ± SD) 863 ± 446 1240 ±439∗∗
r-ATG 0 1
IVIg 1 0
TPE, IVIg 1 0
TPE, rituximab 1 (2%) 6 (17%)
Upward adjustment of
immunosuppression 11 (24%) 3 (8%)
SR:subclinicalrejection,CR:clinicalrejection,r-ATG:rabbit-antithymocyte
globulin, IVIg: intravenous immunoglobulin, TPE: therapeutic plasma-
pheresis.
∗P = .06 for overall diﬀerence in category of treatment.
∗∗P = .003.
survival was 72% for the borderline group, 83% for the
combined acute rejection group, and 97% in the control
group.
The timing of the acute rejection after transplantation
did not appear to have a signiﬁcant impact on death-
censored graft survival. For this analysis we combined the
two rejection groups and determined the graft survival
for patients with rejection occurring more than 180 days
compared to those with rejection occurring less than 1806 Journal of Transplantation







Death or graft loss 22 (5.9%) 7 (15%)∗ 9 (25%)∗
Death with function
graft (DWFG) 13 (3.5%) 3 (6.5%) 2 (5.6%)
Graft loss 9 (2.4%) 4 (8.7%)∗ 7 (19.4%)∗
Causes of graft loss
IFTA 2 3 2
Glomerular/vascular 3 0 1
Nonadherence 3 0 1
Acute Rejection 0 1 1
BK nephropathy 1 0 0
Primary non function 0 0 1
Transplant
pyelonephritis 001
SR: subclinicalacute rejection, CR: clinicalacute rejection, IFTA: interstitial
ﬁbrosis and tubularatrophy.
∗P<. 05 compared to no rejection group.
days post transplantation. The Kaplan-Meier estimate of the
5-year graft survival was 81.8% in those with acute rejection
occurring more than 180 days compared to 80.6% in those
with rejection less then 180 days post transplantation (HR
1.17, CI 0.32–4.22).
3.3. Causes of Graft Failure. The causes of graft failure are
shown in Table 6. If it is assumed that graft losses from IFTA
(n = 7) and acute rejection (n = 2) are the phenotypes
of immune graft losses, then 64% of the grafts lost in
the two rejection groups are potentially immune related
compared to 22% in the control group, but this diﬀerence
was not statistically signiﬁcant. None of the graft losses were
attributed to progressive transplant glomerulopathy. Four of
the graft losses were attributed to nonadherence including
3 of the 9 in the control group. It is likely that these grafts
had acute rejection but there was no biopsy conﬁrmation so
they were put in a separate category. If these 3 patients in the
controlgroup had been assigned toone ofthe acuterejection
groupsthe diﬀerencesin graft survival would have beeneven
greater.
4.Discussion
In this study of kidney transplant recipients treated with
a rapid steroid withdrawal protocol clinical acute rejection
occurred in 7.8% of patients which is similar to previous
studies of early steroid withdrawal [13, 14]. One unique
aspect of our study is the inclusion of protocol biopsies
which demonstrated subclinical Banﬀ borderline changes or
acuterejection occurredinan additional10%ofthepatients.
Our results show that both of these rejection groups were
associated with inferior graft survival. The Kaplan-Meier
estimate of the death-censored graft survival at 5 years post
transplantation was 78% and 81% in the CR and SR groups,
respectively, compared to 97% in the control group without
rejection.
Banﬀ borderline changes (t1, t2, or t3 with i0 or i1), as
the term implies, do not reach the level of acute rejection
by the Banﬀ criteria (i.e., minimum of i2, t2) [15]. But
when we combined the two rejection groups (SR and CR)
we found that patients with Banﬀ borderline changes had
a worse outcome compared to the control group without
rejection. The 5-year estimated death-censored graft survival
was 72% for the borderline group, 83% for the combined
acute rejection group, and 97% in the control group. This
ﬁndinghelpsjustifytheinclusionofBanﬀborderlinechanges
in the analysis of the impact of acute rejection on death-
censored graft survival in this study of patients on an RSW
immunosuppression protocol.
Our data also showed that on followup 1 year protocol
biopsies both the rejection groups have more persistent
inﬂammation (i.e., higher Banﬀ i and t scores) compared to
the control group. In addition, there was a larger proportion
of patients in both rejection groups with the combination of
IFTA and persistent inﬂammation on the followup protocol
biopsy done at 1 year (Table 4). Previous studies have shown
that the combination of IFTA with inﬂammation on a
protocol biopsy correlated with a higher risk of subsequent
graft failure compared to IFTA alone [16, 17].
There were some diﬀerences in the treatment of the
rejections between the groups which may have inﬂuenced
the outcome. For example, the average number of doses (2.5
versus 1.7) and average total dose of pulse corticosteroids
in mg (1240 ± 439 versus 863 ± 446) were higher in the
CR group compared to the SR group. It is feasible that less
aggressive treatment of rejections in the SR group couldhave
contributedtoa worse outcome,butourdataisnot adequate
to address the impact of treatment on outcome.
In our study the time interval from transplant to acute
rejectiondidnotappeartohaveanimpactondeath-censored
graft survival. The Kaplan-Meier estimate of the 5-year graft
survival was 81.8% for those with acute rejection occurring
greater than 180 days compared to 80.6% in those with
rejection occurring less than 180 days post transplantation
(HR 1.17, CI 0.32–4.22).
Data from previous studies has suggested that late acute
rejection has a greater negative impact on graft survival
compared to the early acute rejection [10, 11, 18–20]. In
a recent study of more than 28,000 deceased donor kidney
transplant recipients, Opelz and D¨ ohler showed that late
acute rejection has a progressive negative impact on graft
survival [10]. In an analysis of the USRDS database, Leggat
et al found that the 4-year graft survival for deceased donor
recipients was 54% and 69% for acute rejection occurring
between 7–12 months and 1–6 months post transplantation,
respectively [11]. In a single center study, Matas et al.
showed that acute rejection occurring more than 1 year
posttransplant was associated with a lower graft half-life for
both living and deceased donor recipients [18]. In another
single center study of deceased donor transplant recipients,
Joseph et al. found that acute rejection occurring more than
3 months post transplantation had a greater negative impact
on graft survival [19].Journal of Transplantation 7
There are some possible explanations for the lack of an
impact of late rejection on graft survival in our study. Our
study included protocol biopsies which may allow for an
earlier diagnosis of acute rejection, particularly during the
later follow-up period. It is also possible that our study is
merely underpowered to show the diﬀerencein graft survival
for late rejection.
Although ourdata suggests that the time from transplant
to biopsy-proven acute rejection is longer in the SR group
(median days to acute rejection is 130 days in the SR group
and 19 days in the CR group), it is feasible that the rejection
process was present for some time before it was conﬁrmed
by biopsy. As a result the true diﬀerences in the time of
onset of the acute rejection may be less than we estimate.
PreviousstudieshaveconﬁrmedthatSRcanpersist forweeks
or months without an apparent change in serum creatinine
or GFR [21, 22].
In our study, death with a function graft accounted for
47% [18] of the grafts lost. This is similar to the study by
El-Zoghby et al., where they attributed 43% of grafts lost to
DWFG [23]. After we excluded the 18 patients with death
with a function graft there were 20 additional grafts lost.
When we classiﬁed the cause of graft loss for these 20 grafts,
35% were attributed to progressive IFTA and 10% to acute
rejection.
If we assume that IFTA and acute rejection are the
phenotypes for immunologic graft loss, then 64% of the
grafts in the acute rejection groups were in these two groups
compared to 22% for the control group, but this diﬀerence
was not statistically signiﬁcant. We caution that the method
ofattributingthecauseofgraftfailureisinherentlysubjective
and there are currently no biomarkers available to identify
the precise mechanism of graft failure. In a the study of
153 grafts losses censored for death with a function graft
El-Zoghby et al. attributed 11.7% of graft losses to acute
rejection and 30.7% to IFTA [23], which is similar to the
ﬁndings in our study.
The diﬀerence in graft survival between the rejection
groups and the control group is estimated to be 15% at 5
years. Previous studies have shown a similar impact of acute
r e j e c t i o no ng r a f ts u r v i v a l[ 5, 24, 25]. In a study of patients
getting protocol biopsies at two weeks post transplantation,
Choi et al. showed that acute rejection was associated with
inferior graft survival [5]. At 5 years posttransplant, graft
survival was 78% in the group with acute rejection and
96% in the group without rejection. In another study of 589
deceased donor kidney recipients, Pirsch et al. showed that
acute rejection was the single most important risk factor for
subsequent graft loss. The 5-year graft survival was 79% for
recipients who had acute rejection and 95% for those with
no rejection [24].Inanothersinglecenterstudy,Knightetal.
demonstrated the impact of acute rejection on graft survival.
Graftsurvival at5yearsposttransplant forrecipientsofliving
donors was 73% for the rejection group and 90% in the
control group while for deceased donors, graft survival was
40% in the rejection group and 88% in the control group
[25].
We conclude that, in kidney transplant recipients on
a rapid steroid withdrawal protocol, acute rejection both
clinical and subclinical rejection are associated with infe-
rior graft survival. In addition, more controlled stud-
ies of the beneﬁts of treating subclinical rejection are
needed.
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